Scarica l'app Stockscreener
57.68
1.67%
0.95
Dopo l'orario di chiusura:
57.68
Anaptysbio Inc Borsa (ANAB) Ultime notizie
AnaptysBio, Inc. Common Stock When Issued (ANABV) Stock Price, News, Quote & History - Yahoo! Finance Canada
Assessing AnaptysBio (ANAB) Valuation After New US$100 Million Buyback And Cancelled Equity Offerings - Yahoo Finance
J.P. Morgan Maintains AnaptysBio(ANAB.US) With Buy Rating, Announces Target Price $69 - moomoo.com
Director Susannah Gray at AnaptysBio (ANAB) submits initial Form 3 - Stock Titan
ANAB Technical Analysis & Stock Price Forecast - Intellectia AI
Anaptys to spin-off First Tracks Biotherapeutics, announces $100M buyback - msn.com
ANABV|AnaptysBio Ord Shs|| - TradingKey
First Tracks Biotherapeutics to be spun off from AnaptysBio, Nasdaq trading set for April 20 By Investing.com - Investing.com South Africa
First Tracks Biotherapeutics to be spun off from AnaptysBio, Nasdaq trading set for April 20 - Investing.com
Insider Selling: AnaptysBio (NASDAQ:ANAB) Director Sells 20,645 Shares of Stock - MarketBeat
Aug Highlights: Can AnaptysBio Inc grow without external funding2026 Valuation Update & Weekly High Return Stock Forecasts - baoquankhu1.vn
AnaptysBio Insider Sold Shares Worth $1,158,451, According to a Recent SEC Filing - marketscreener.com
ANAB Stock Price, Quote & Chart | ANAPTYSBIO INC (NASDAQ:ANAB) - ChartMill
Director John Schmid Sells 20,645 Shares of AnaptysBio Inc (ANAB) - GuruFocus
Anaptysbio director Schmid sells $1.16 million in stock By Investing.com - Investing.com Canada
[Form 4] ANAPTYSBIO, INC Insider Trading Activity - Stock Titan
AnaptysBio Director Sold Shares Worth Over $1.1M - TradingView
Aug Volume: Is AnaptysBio Inc stock a good dividend stock2026 Reactions & Smart Money Movement Tracker - baoquankhu1.vn
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Wedbush Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $75 - Moomoo
ANAB: Piper Sandler Raises Price Target to $95.00, Maintains Ove - GuruFocus
ANAB: Piper Sandler Raises Price Target to $95.00, Maintains Overweight Rating | ANAB Stock News - GuruFocus
Piper Sandler Raises AnaptysBio (NASDAQ:ANAB) Price Target to $95.00 - MarketBeat
Piper Sandler raises AnaptysBio stock price target to $95 from $67 - Investing.com Canada
H.C. Wainwright reiterates Buy on AnaptysBio stock after spinoff news By Investing.com - Investing.com Canada
HC Wainwright & Co. Reiterates Buy Rating on AnaptysBio (ANAB) | - GuruFocus
[144] ANAPTYSBIO, INC SEC Filing - Stock Titan
H.C. Wainwright Maintains AnaptysBio(ANAB.US) With Buy Rating, Raises Target Price to $66 - Moomoo
ANAB SEC FilingsAnaptysbio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update - marketscreener.com
AnaptysBio (NASDAQ:ANAB) Given Buy Rating at HC Wainwright - MarketBeat
AnaptysBio Insider Sold Shares Worth $1,089,199, According to a Recent SEC Filing - marketscreener.com
AnaptysBio Spin Off Reshapes Risk Profile With New Royalty Focus - Sahm
AnaptysBio (ANAB) price target increased by 21.16% to 79.82 - MSN
Biotech Startup First Tracks Secures $145M in Private Funding - National Today
(ANAB) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
AnaptysBio authorizes $100M stock buyback, plans spin-off By Investing.com - Investing.com Australia
AnaptysBio sets April 20 spin-off date for First Tracks Bio - Investing.com Australia
AnaptysBio (NASDAQ:ANAB) CEO Daniel Faga Sells 17,679 Shares - MarketBeat
AnaptysBio Authorizes $100 Billion Buyback Plan - National Today
AnaptysBio (NASDAQ:ANAB) Board of Directors Authorizes Share Buyback Plan - MarketBeat
Anaptysbio CEO Faga sells $1.1 million in shares By Investing.com - Investing.com Australia
AnaptysBio spinoff First Tracks Bio raises $80M in placement By Investing.com - Investing.com India
AnaptysBio (NASDAQ: ANAB) CEO gets PSU grant and sells shares for tax - Stock Titan
Anaptysbio CEO Faga sells $1.1 million in shares - Investing.com
Anaptysbio, Inc. Appoints Susannah Gray to the Board of Directors - marketscreener.com
Anaptysbio, Inc. Announces Managing the Financial Collaborations for Jemperli with Gsk and Imsidolimab with Vanda - MarketScreener
AnaptysBio Board Approves Spin-Off of First Tracks Bio, Repurchase of $100 Million Shares - Moomoo
AnaptysBio Advances First Tracks Spin-Off and Governance Changes - TipRanks
Sector Update: Health Care Stocks Retreat Friday Afternoon - Moomoo
AnaptysBio (NASDAQ:ANAB) Shares Down 10.3%Time to Sell? - MarketBeat
AnaptysBio Announces $100 Million Stock Repurchase Program and Updates on Clinical Development Progress - geneonline.com
AnaptysBio authorizes $100M stock buyback, plans spin-off - Investing.com
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):